C4 Therapeutics, Inc. Share Price
NASDAQ: CCCC | Small CapC4 Therapeutics, Inc. Stock Performance
Open $4.05 | Prev. Close $4.09 | Circuit Range N/A |
Day Range $3.83 - $4.06 | Year Range $1.70 - $5.17 | Volume 84,130 |
Average Traded $3.91 |
C4 Therapeutics, Inc. Share Price Today
As of 29 August 2026, C4 Therapeutics, Inc.'s share price is $3.85. The stock opened at $4.05, compared to its previous close of $4.09. During today's trading session, C4 Therapeutics, Inc.'s share price traded between $3.83 and $4.06, with an average price of $3.95. Over the past 52 weeks, the stock has recorded a high of $5.17 and a low of $1.70. In terms of performance, C4 Therapeutics, Inc.'s share price has risen by 42.33% over the last six months and is up 48.36% on a year-on-year basis.
C4 Therapeutics, Inc. Share Price Chart
C4 Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $319.14M | PE Ratio (TTM) -3.03 | Dividend Yield N/A |
EPS (TTM) $-1.27 | Revenue (TTM) $35.95M | Return On Equity (TTM) -40.92% |
Profit Margin -292.08% | Debt to Equity 0.13 | Quarterly Earnings Growth YoY -30.41% |
C4 Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
C4 Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $3.46 | $4.09 | +17.19% |
Jul 2026 | $4.71 | $3.49 | -24.95% |
Jun 2026 | $4.34 | $4.65 | +5.92% |
May 2026 | $2.77 | $4.39 | +55.12% |
Apr 2026 | $2.67 | $2.83 | +7.60% |
Mar 2026 | $2.63 | $2.63 | -2.77% |
Feb 2026 | $1.89 | $2.71 | +43.12% |
Jan 2026 | $1.97 | $1.89 | -1.05% |
Dec 2025 | $2.60 | $1.91 | -29.26% |
Nov 2025 | $2.60 | $2.70 | +3.65% |
Oct 2025 | $2.23 | $2.60 | +17.34% |
Sep 2025 | $2.55 | $2.22 | -14.45% |
CCCC Share Price FAQs
What is C4 Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of C4 Therapeutics, Inc. stock?
What is CCCC's market capitalisation today?
What is CCCC's net income for the last quarter?
What is the 5 year returns of CCCC?
What is the high & low stock price of CCCC today?
Can I buy CCCC shares in India?